Pharmaceutical - Pharmaceutical, Japan

Filter

Current filters:

PharmaceuticalJapan

Popular Filters

1 to 25 of 94 results

Kyorin grants R-Pharm exclusive rights to OAB drug imidafenacin in Russia

Kyorin grants R-Pharm exclusive rights to OAB drug imidafenacin in Russia

15-10-2014

Japanese drugmaker Kyorin Pharmaceutical and R-Pharm, one of Russia’s largest pharmaceutical producers,…

Genito-urinaryimidafenacinJapanKyorin PharmaceuticalsLicensingOno PharmaceuticalPharmaceuticalR-PharmRussiaStayblaUritos

GlaxoSmithKline takes stake in new Aspen Japanese unit

GlaxoSmithKline takes stake in new Aspen Japanese unit

09-10-2014

South African drugmaker Aspen Pharmacare says that Aspen Global Inc, a subsidiary of Aspen Holdings,…

Aspen PharmacareGlaxoSmithKlineJapanMarkets & MarketingMergers & AcquisitionsPharmaceutical

Positive new findings for Astellas’ isavuconazole in mucormycosis

Positive new findings for Astellas’ isavuconazole in mucormycosis

08-10-2014

Japanese drug major Astellas Pharma says that isavuconazole demonstrated successful outcomes in the treatment…

Antibiotics and Infectious diseasesAstellas PharmaisavuconazoleJapanPharmaceuticalResearch

Takeda appoints John Boslego as senior vice president of its global vaccine business unit

Takeda appoints John Boslego as senior vice president of its global vaccine business unit

08-10-2014

Japan’s largest drugmaker Takeda Pharmaceutical has appointed John Boslego as senior vice president…

Anti-viralsBoardroomJapanPharmaceuticalTakeda Pharmaceutical

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

Perosphere and Daiichi Sankyo collaborate on Ph III study of PER977 with edoxaban

07-10-2014

USA-based Perosphere has entered into a third clinical trial collaboration agreement with Japanese pharma…

Cardio-vascularDaiichi SankyoedoxabanHematologyJapanPER977PerospherePharmaceuticalPortola PharmaceuticalsResearch

Teijin begins construction on $20 million site in western Japan

Teijin begins construction on $20 million site in western Japan

06-10-2014

Japanese pharma company Teijin is to build a Technology Integrated Pharmaceutics Center to leverage the…

JapanPharmaceuticalProductionTechnology Integrated Pharmaceutics CenterTeijin

Takeda responds to verdict in US Actos case; invests in vaccines firm

Takeda responds to verdict in US Actos case; invests in vaccines firm

06-10-2014

The US subsidiary of Japan’s largest drugmaker Takeda Pharmaceuticals says that in the case of Frances…

ActosAlfresa CorpDiabetesJapanLegalMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalUSAVaccine Safe CoVaccines

Daiichi Sankyo seeks wider indication for Cravit in Japan

Daiichi Sankyo seeks wider indication for Cravit in Japan

03-10-2014

Japanese drug major Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) in Japan…

Antibiotics and Infectious diseasesCravitDaiichi SankyoJapanPharmaceuticalRegulation

Takeda presents Phase III data for Entyvio in UC and Crohn’s Disease

Takeda presents Phase III data for Entyvio in UC and Crohn’s Disease

02-10-2014

Japan’s largest drugmaker Takeda Pharmaceutical today announced new data from a Phase III study of…

EntyvioGastro-intestinalsJapanPharmaceuticalResearchTakeda Pharma

ESMO 2014: Eisai’s Halaven could provide better quality of life for breast cancer patients

ESMO 2014: Eisai’s Halaven could provide better quality of life for breast cancer patients

01-10-2014

Data posters presented at this year’s European Society for Medical Oncology (ESMO) Congress in Madrid,…

EisaiHalavenJapanOncologyPharmaceuticalResearchSpain

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

ESMO 2014: Eisai’s lenvatinib could revolutionize treatment of rare thyroid cancer

30-09-2014

An orphan drug could offer real hope to patients with rare thyroid cancer, Japanese drugmaker Eisai revealed…

EisaiInterviewsJapanlenvatinibOncologyPharmaceuticalResearch

Added indication for Daiichi Sankyo’s Lixiana in Japan

Added indication for Daiichi Sankyo’s Lixiana in Japan

29-09-2014

The Japanese Ministry of Health, Labor and Welfare has granted approval for domestic pharma major Daiichi…

Cardio-vascularDaiichi SankyoJapanLixianaPharmaceuticalRegulation

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

26-09-2014

The non-Hodgkin lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia,…

AdcetrisAustraliaChinaGazyvaroIndiaJapanMarkets & MarketingOncologyPharmaceuticalRocheTakeda Pharmaceutical

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Mitsubishi Tanabe Pharma gains approval for Telavic in genotype 2 HCV

Mitsubishi Tanabe Pharma gains approval for Telavic in genotype 2 HCV

22-09-2014

Japanese pharma company Mitsubishi Tanabe Pharma has received approval for an additional indication of…

Anti-viralsJapanMitsubishi TanabePharmaceuticalRegulationTelavic

Bayer’s Eylea approved in Japan for myopic CNV

Bayer’s Eylea approved in Japan for myopic CNV

22-09-2014

Bayer Yakuhin, the Japanese health care subsidiary if Germany’s Bayer has received approval from Japan’s…

BayerEyleaJapanOphthalmicsPharmaceuticalRegeneron PharmaceuticalsRegulation

First Ph III data in Japanese patients for Merck’s omarigliptin for type 2 diabetes

18-09-2014

US pharma giant Merck & Co has announced the presentation of the first data from the Phase III clinical…

DiabetesJapanMerck & CoomarigliptinPharmaceuticalRegulationResearch

Rheumatoid arthritis drug market will grow to $18.2 billion in 2023, report

17-09-2014

The rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion…

Anti-Arthritics/RheumaticsbaricitinibBiosimilarsEli LillyEuropeIncyteJapanMarkets & MarketingPfizerPharmaceuticalUSAVertexXeljanz

Meiji and Takeda to co-promote Rozerem for insomnia

Meiji and Takeda to co-promote Rozerem for insomnia

08-09-2014

Fellow Japanese drugmakers Meiji Seika Pharma and Takeda Pharmaceutical have finalized a co-promotion…

JapanLicensingMeiji Seika PharmaNeurologicalPharmaceuticalRozeremTakeda Pharmaceutical

1 to 25 of 94 results

Back to top